Who are Intradermal injection of Mycobacterium w's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Levagen+, diphenylcyclopropenone (DPCP), beta-1,3-glucan, Bacterial Lysates, Echinaforce Forte tablets, OM-85 BV.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/intradermal-injection-of-mycobacterium-w.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Intradermal injection of Mycobacterium w — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intradermal injection of Mycobacterium w (Intradermal injection of Mycobacterium w) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunostimulant; mycobacterial vaccine. Area: Immunology; Oncology.

phase 3 Immunostimulant; mycobacterial vaccine Immunology; Oncology Biologic Live · refreshed every 30 min

Target snapshot

Intradermal injection of Mycobacterium w (Intradermal injection of Mycobacterium w) — Ministry of Science and Technology, India. Intradermal injection of Mycobacterium w stimulates innate and adaptive immune responses to enhance anti-tumor or anti-infectious immunity.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Intradermal injection of Mycobacterium w TARGET	Intradermal injection of Mycobacterium w	Ministry of Science and Technology, India	phase 3	Immunostimulant; mycobacterial vaccine
Levagen+	Levagen+	RDC Clinical Pty Ltd	marketed	Immunostimulant	Immune cell activation (non-specific)
diphenylcyclopropenone (DPCP)	diphenylcyclopropenone (DPCP)	Ain Shams University	marketed	Contact sensitizer / Immunostimulant
beta-1,3-glucan	beta-1,3-glucan	Meiji University of Oriental Medicine	marketed	Immunostimulant / Biological response modifier	Dectin-1 (and other pattern recognition receptors)
Bacterial Lysates	Bacterial Lysates	Sanofi	marketed	Immunostimulant; bacterial lysate
Echinaforce Forte tablets	Echinaforce Forte tablets	A. Vogel AG	marketed	Herbal immunostimulant
OM-85 BV	OM-85 BV	Chinese Academy of Medical Sciences	marketed	Bacterial lysate immunostimulant

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunostimulant; mycobacterial vaccine class)

Ministry of Science and Technology, India · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Intradermal injection of Mycobacterium w — Competitive Intelligence Brief. https://druglandscape.com/ci/intradermal-injection-of-mycobacterium-w. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab